VB10.2210 / Nykode Therap - LARVOL DELTA

SARS-CoV-2T-cell vaccine VB10.2210 induces broad T-cell responses in a phase 1/2 open-label clinical trial. (PubMed, Vaccine) - P1/2 | "Expansion of VB10.2210 specific T-cell clones was confirmed by TCR sequencing. Further studies are needed to evaluate the clinical benefit of DNA vaccines inducing broad virus specific T-cell immunity in preventing severe COVID-19 or as treatment of patients with persistent infection."

First-in-human • Journal • P1/2 data • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • CD8

A Phase 1/2 Study to Determine Safety and Immunogenicity of Two COVID 19 Vaccines VB10.2129 (RBD Candidate) and VB10.2210 (T Cell Candidate) Previously Vaccinated in Healthy Adult Volunteers (clinicaltrials.gov) - P1/2 | N=68 | Completed | Sponsor: Nykode Therapeutics ASA | Active, not recruiting ➔ Completed | N=160 ➔ 68 | Trial completion date: Oct 2023 ➔ May 2023

Enrollment change • Trial completion • Trial completion date • Infectious Disease • Novel Coronavirus Disease

Antigen presenting cell targeted T cell DNA vaccine inducing strong and specific cellular responses across multiple T cell epitopes of SARS-COV-2 (P661) (IMMUNOLOGY 2023) - P1/2 | "Preclinical data in these three mouse models demonstrate that VB10.2210 consistently induced strong, broad, dose-dependent, and persistent T cell responses across multiple T cell epitopes. VB10.2210 is currently being evaluated for safety and immunogenicity in a Phase I clinical trial (NCT05069623)."

Late-breaking abstract • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

A Phase 1/2 Study to Determine Safety and Immunogenicity of Two COVID 19 Vaccines VB10.2129 (RBD Candidate) and VB10.2210 (T Cell Candidate) Previously Vaccinated in Healthy Adult Volunteers (clinicaltrials.gov) - P1/2 | N=160 | Active, not recruiting | Sponsor: Nykode Therapeutics ASA | Recruiting ➔ Active, not recruiting

Enrollment closed • Infectious Disease • Novel Coronavirus Disease